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OBJECTIVES The purpose of this study was to test whether the HindIII (1) and PvuII (2) or (1)
restriction enzyme–defined alleles are associated with angiographic coronary artery disease
(CAD).
BACKGROUND Lipoprotein lipase (LPL) plays a central role in lipid metabolism, hydrolyzing triglyceride in
chylomicrons and very low density lipoproteins. Polymorphic variants of the LPL gene are
common and might affect risk of CAD.
METHODS Blood was drawn from 725 patients undergoing coronary angiography. Leukocyte deoxyri-
bonucleic acid segments containing the genomic sites were amplified by the polymerase chain
reaction and digested, and polymorphisms were identified after electrophoresis in 1.5%
agarose gel.
RESULTS In no-CAD control subjects (n 5 168), HindIII (2) and (1) allelic frequencies were 28.6%
and 71.4%, and (2) and (1) alleles were carried by 44.0% and 86.9% of subjects, respectively.
Control PvuII (2) and (1) allelic frequencies were 41.7% and 58.3%, and (2) and (1) alleles
were carried by 64.3% and 81.0%, respectively. In CAD patients (.60% stenosis; n 5 483),
HindIII (1) allelic carriage was increased (93.8% of patients, odds ratio [OR] 5 2.28,
confidence interval [CI] 1.27 to 4.00). Also, PvuII (2) allelic carriage tended to be more
frequent in CAD patients (OR 5 1.33, CI 0.92 to 1.93). Adjusted for six CAD risk factors
and the other polymorphism, HindIII (1) carriage was associated with an OR 5 2.86, CI
1.50 to 5.42, p 5 0.0014, and PvuII (2) carriage, OR 5 1.42, CI 0.95 to 2.12, p 5 0.09.
The two polymorphisms were in strong linkage disequilibrium, and a haplotype association
was suggested.
CONCLUSIONS The common LPL polymorphic allele, HindIII (1), is moderately associated with CAD, and
the PvuII (2) allele is modestly associated (trend). Genetic variants of LPL deserve further
evaluation as risk factors for CAD. (J Am Coll Cardiol 1999;33:1013–20) © 1999 by the
American College of Cardiology
Atherosclerotic cardiovascular disease, predominantly coro-
nary artery disease (CAD), is the single greatest cause of
mortality in the United States, being responsible for about
one third of all deaths annually (1). Coronary artery disease
shows strong familial aggregation, especially when it pre-
sents at an early age and when many relatives are affected
(2). Dyslipidemias form a well known risk factor for CAD;
however, only a small percentage of CAD patients have
recognized monogenetic disease due to dysfunctional mu-
tations in lipoproteins or lipoprotein-related genes (e.g.,
receptors, catabolic enzymes) (2). Thus, as much as one half
of risk remains unexplained (2,3) and is believed to be due
to the interaction of multifactorial inheritance and environ-
mental factors (e.g., diet, exercise, tobacco) (2). In this
regard, common variants of genes central to lipid metabo-
lism that are associated with modest changes in protein
function might be important contributors to risk at a
population level, perhaps in association with other specific
environmental and genetic factors (2,4).
The lipoprotein lipase (LPL) gene represents an excellent
candidate to explain portions of the genetically determined
risk of atherosclerosis (5). Mature LPL is a 448 amino acid
glycoprotein with chromosomal location 8p22 (6,7). It is
one of about 15 genetically mapped, lipid-related proteins
known to be capable of contributing to CAD risk (2).
Lipoprotein lipase, strategically anchored to vascular endo-
thelium, plays a central role in lipid metabolism. Lipopro-
tein lipase–catalyzed hydrolysis of triglycerides constitutes
the rate-limiting step in the removal of triglyceride-rich
lipoproteins such as chylomicrons and very low density
lipoproteins (VLDLs) from the circulation (8,9). Lipopro-
tein lipase is multifunctional, recently having been shown to
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serve as a ligand for low density lipoprotein (LDL) receptor–
related protein and to influence the hepatic secretion and
uptake of VLDL and LDL cholesterol (10). Rare LPL
mutations are known that cause marked dyslipidemias (e.g.,
familial LPL deficiency with chylomicronemia [8,11]), at
least some of which are known to be associated with
premature atherosclerosis (11). However, we were interested
in exploring whether common variants of LPL (i.e., allele
frequency $0.20) might contribute importantly to risk for
CAD at a population level through subtle changes in LPL
function associated with milder clinical phenotypes.
Several polymorphic variants of the LPL gene have been
identified in recent years and evaluated for their effects on
plasma lipids and atherosclerosis risk (11–24). Those defined
by the HindIII and PvuII restriction fragment length polymor-
phism sites, located on introns 8 and 6, respectively, of the
LPL gene, are common and may be associated with subtle
alterations in plasma lipids. The HindIII (1) allele or the
HindIII (1/1) genotype has been reported to be associated
with an atherogenic profile (elevated triglycerides and/or de-
creased high density lipoprotein [HDL] cholesterol), and the
HindIII and PvuII polymorphisms have been variably reported
to associate with CAD (12,14,16,17,19,20,22). However, the
studies often have been small and the results inconsistent.
Polymorphisms in genes related to CAD pathophysiology
often have required multiple and large studies to clearly define
attributable genetic risk (4,25–27).
Given the importance of LPL as a candidate gene for
CAD risk, we prospectively evaluated a large, independent,
well defined, ethnically relatively homogeneous and angio-
graphically controlled study population to determine
whether the HindIII and PvuII polymorphisms were asso-
ciated with angiographically defined CAD.
METHODS
Study hypotheses. We tested whether: 1) carriage of the
more common HindIII (1) variant allele would be CAD-
associated (13,16,17,19,20,22,23), and 2) carriage of either
the PvuII (1) (more common) or PvuII (2) (less common)
alleles (12,16,19–22) would be disease-associated in pa-
tients whose coronary status was defined by angiography.
Patient and control populations. Study patients and con-
trol subjects consisted of consecutive consenting subjects pre-
senting for coronary angiography at LDS Hospital because of
either symptoms relating to suspected CAD or unrelated
conditions requiring angiographic evaluation (e.g., valvular
disease, cardiomyopathy). Included subjects were of unre-
stricted age and gender who gave written informed consent for
a blood draw at the time of angiography for deoxyribonucleic
acid (DNA) extraction to be used in studies approved by the
hospital’s institutional review board. Subjects were residents of
Utah, southwestern Idaho or southeastern Wyoming, a pop-
ulation that is ethnically primarily of northern European
(Anglo-Scandinavian) descent, and which has previously been
shown to be genetically representative of North American
Caucasians (28).
Key demographic characteristics of subjects were re-
corded on computerized angiographic data forms, including
age, gender and past history of myocardial infarction (MI)
(4). Assessment of CAD was made by review of angiograms
by the patient’s cardiologist, who was uninformed as to LPL
genotypes. Results were entered into the computer database
in a format modified after the Coronary Artery Surgery
Study protocol (4,25,29,30). Patients were designated as
having significant CAD if they had .60% stenosis of at
least one coronary artery or major branch and no CAD if
,10% stenosis was present. Of the 483 CAD patients, 172
presented for angiography with a history of MI (acute or
recent onset MI in 109), 176 with unstable angina, 141 with
other chest pain syndromes, 72 with valvular heart disease
and 1 with cardiomyopathy, singly or in combination. Of
the 168 control subjects with normal coronary arteries, 108
presented for angiography with chest pain syndromes with-
out CAD, 45 with valvular disease and 6 with cardiomyop-
athy, singly or in combination, or other indications. Patients
with minor CAD (10% to 60% stenosis; n 5 74) were
designated as having an “indeterminate” CAD status and
were not included in the comparative analyses.
Deoxyribonucleic acid extraction. Approximately 20 to
30 ml of blood was withdrawn by venipuncture at the time
of coronary angiography and collected in ethylenediami-
netetraacetic acid. The leukocyte buffer coat was separated
by centrifugation and genomic DNA prepared using a
standard phenol extraction, isopropanol precipitation
method as previously described (25,26).
Genotyping. Genotyping was performed by polymerase
chain reaction amplification of the polymorphic regions found
in introns eight and six followed by digestion of these amplified
fragments with HindIII and PvuII restriction endonucleases,
respectively.
The region in intron 8 containing the HindIII polymor-
phism was amplified using the following primer pair (16):
LPL-H1 59-TGA AGC TCA AAT GGA AGA GT-39,
LPL-H2 59-TCA AAG CAA ATG ACT AAA-39. The
amplification protocol consisted of a denaturing segment
(94°C, 1 min), an annealing segment (53°C, 45 s) and an
Abbreviations and Acronyms
CAD 5 coronary artery disease
CI 5 confidence intervals
DNA 5 deoxyribonucleic acid
HDL 5 high density lipoprotein
LDL 5 low density lipoprotein
LPL 5 lipoprotein lipase
MI 5 myocardial infarction
OR 5 odds ratio
VLDL 5 very low density lipoprotein
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extension segment (72°C, 1 min), repeated for 35 cycles
with a final extension for 7 min. The amplified product is
770 bp in size.
The amplification of the PvuII-containing site (intron 6)
used the following primer pair (16): LPL-P1 59-ATG
GCA CCC ATG TGT AAG GTG-39, LPL-P2 59-GTG
AAC TTC TGA TAA CAA TCT C-39. The amplifica-
tion protocol consisted of a denaturing segment (94°C,
20 s), an annealing segment (50°C, 30 s) and an extension
segment (72°C, 20 s), repeated for 30 cycles with a final
extension for 7 min. The amplified product is 440 bp in size.
For restriction enzyme digestion, both enzymes (Gibco
BRL) were used in a concentration of 10 U in 18 ml (final
volume) with an appropriate buffer as recommended by the
manufacturer. Polymerase chain reaction products were
digested for 3 to 5 h 37°C, and digested products were
electrophoresed through a 1.5% agarose gel for 2.5 to 3 h.
Products were visualized by staining with ethidium bromide
(1 mg/ml). When present, the HindIII site (intron 8)
produces a 600-bp fragment after digestion. The PvuII
restriction site (intron 6) yields 330-bp and 110-bp frag-
ments.
Genotypes were scored by an experienced reader blinded
to clinical and angiographic results. Representative gels are
shown in Figure 1. Our convention was to refer to the
polymorphic allele displaying the restriction site as (1) and
the allele without the site as (2). For both PvuII and
HindIII, the (2) allele was less common.
Statistical planning and analysis. In epidemiologic studies,
an initial report of an association with an odds ratio of 2 or
more is generally considered to be of interest (31). However,
common genetic factors associated with even smaller odds
ratios ('1.5) for multifactorial diseases such as CAD also may
be of interest. Thus, a sample size was calculated that would
provide adequate power to determine an odds ratio of 1.5 to
2.0 for an association with CAD. For LPL HindIII (1) allelic
carriage, occurring in '80% of control subjects, a sample size
of 260 to 683 subjects per group would be required; for the
PvuII (2) polymorphic allele, with a '60% carriage rate in
control subjects, the required size is 152 to 421 subjects per
group, assuming a power of 80% at a two-sided alpha level of
0.05. We assembled and studied a population of '725 sub-
jects; 67% of the population sampled had severe CAD and
27% had a history of MI.
A chi-square analysis was used to evaluate the allelic and
genotypic frequencies that were calculated from the ob-
served genotypic counts and to assess Hardy–Weinberg
expectations. The same methodology was applied to com-
parisons between allelic and genotypic frequencies. Associ-
ations were determined as odds ratios (ORs) and 95%
confidence intervals (CIs) as previously described (32). (The
odds of carrying a specific allele is defined as the frequency
of subjects in whom it occurs divided by the frequency of
subjects in whom it does not occur. The odds ratio for CAD
is the odds of allelic carriage in the diseased [CAD] group
divided by the odds in the undiseased [no-CAD] group.)
Exploratory analyses were prospectively planned in the
stratified subgroups of interest presented in Figure 2.
Multivariate logistic regression was used to determine ad-
justed ORs for the genetic markers, conditioned on the
major CAD risk factors (SPSS 6.1, Chicago, Illinois).
Linkage disequilibrium, the tendency of a specific com-
bination of linked loci to occur on the same chromosomal
homologue more frequently than explained by chance, was
assessed by estimating the observed frequencies of specific
haplotypes, that is, the possible combinations of alleles at
the HindIII and PvuII loci, using the linkage utility pro-
gram EH and comparing it with the expected frequencies
using the likelihood test statistic.
RESULTS
Characteristics of the patient groups. A total of 725
angiographically assessed subjects were studied. Their age
averaged 64 years (range 17 to 89); 196 (27%) had a history
of MI, and 486 (67%) had significant CAD. Their key
identifying characteristics are summarized by patient sub-
group in Table 1. Characteristics of the CAD and no-CAD
control groups were approximately comparable, except that
those with CAD were somewhat older (by 4 years) and
more frequently male (79% vs. 53%) and diabetic (18% vs.
12%), compared with no-CAD control subjects.
Genotypic and allelic frequencies in the control group.
Genotypic and allelic frequencies in the study groups are
shown in Table 2. The HindIII (2) and (1) allelic
frequencies in the pool of no-CAD angiographic control
subjects (n 5 168) were 28.6% and 71.4%, respectively, and
the HindIII (2) and (1) alleles were carried by 44.0% and
Figure 1. Computer-assisted photodocumentation showing exam-
ples of LPL HindIII (left) and PvuII (right) polymorphic geno-
typing using polyacrylamide gel electrophoresis of polymerase
chain reaction amplification products.
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86.9%, respectively, of these subjects. The PvuII (2) and
(1) allelic frequencies in no-CAD control subjects were
41.7% and 58.3%, and the PvuII (2) and (1) alleles were
carried by 64.3% and 81.0% of subjects, respectively. Ge-
notypic distributions in the control groups conformed with
Hardy–Weinberg expectations.
HindIII polymorphism and CAD. Among CAD pa-
tients, HindIII (2) allelic frequency was 26.3% (OR 5
0.89, CI 0.73 to 1.09, p 5 0.42), and HindIII (1) frequency
was 73.7% (OR 5 1.12, CI 0.92 to 1.37). The distribution
of genotypes differed between cases and control subjects
(p 5 0.006).
Carriage of the HindIII (1) variant allele was observed in
93.8% of CAD patients, corresponding to an odds ratio of
2.28, CI 1.27 to 4.00, p 5 0.005, compared with no-CAD
control subjects. Homozygous (1/1) genotypic carriage
was associated with an odds ratio for CAD of 2.02, CI 1.11
to 3.70, p 5 0.02, compared with the homozygous (2/2)
genotype (Table 3).
PvuII polymorphism and CAD. Among CAD patients,
PvuII (2) allelic frequency was 46.2% (OR 1.20, CI 0.93 to
1.54, p 5 0.15, vs. control subjects). Overall, genotypic
distributions did not differ significantly from control sub-
jects. However, carriage of the PvuII (2) variant allele,
present in 70.6% of patients, was associated with a modest
odds ratio trend for CAD: OR 5 1.33, CI 0.92 to 1.93, p 5
Figure 2. Odds ratio (OR) (diamonds 5 point estimates, with 95% confidence intervals [CIs]) for coronary artery disease (CAD) of
carriage of HindIII (1) allele (genotypes 1/1 or 1/2 vs. genotype 2/2) (left), and PvuII (2) allele (genotypes 2/2 or 2/1 vs. 1/1
genotype) (right), for CAD versus no-CAD groups overall (open diamonds) and in prespecified subgroups (black diamonds). Size (area)
of each diamond is proportional to size of respective (sub)group. Scale on abscissa is logarithmic with increments of 0.1 between 0.1 and
1.0 and 1 between 1 and 10. Chol 5 cholesterol; HTN 5 hypertension.
Table 1. Characteristics of CAD Patients and Control Subjects
Characteristic CAD Patients CAD Controls
p
Value
Number 483 168 —
Age (yr) (mean 6 SD) 65 6 10 61 6 12 ,0.001
Range 37 to 89 17 to 84
Gender (% male) 79 53 ,0.001
Hypertension (%) 49 45 0.4
Systolic BP (mm Hg) 139 6 24 140 6 22 0.5
Diastolic BP (mm Hg) 73 6 10 75 6 13 0.08
Smoker (%) 24 21 0.4
Diabetes (%) 18 12 0.05
Cholesterol (mg/dl) 207 6 46 203 6 60 0.6
n 368 91
Cholesterol $220 mg/dl (%) 35 35 0.9
BP 5 blood pressure; CAD 5 coronary artery disease.
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0.13 (Table 3). Carriage of the homozygous (2/2) com-
pared with the (1/1) genotype was associated with an odds
ratio for CAD of 1.39 (CI 0.84 to 2.28) (Table 3).
Associations between polymorphisms and CAD in pre-
specified subgroups. Lipoprotein lipase polymorphisms
might affect risk primarily in certain subgroups (e.g., in
women vs. men or in younger vs. older patients). For both
HindIII (1) and PvuII (2) carriage, there was no signifi-
cant heterogeneity for the associations with CAD among
subgroups. Although some variations in the point estimate
of the ORs between stratified subgroups were observed, the
CIs were broad, and the power was low for these compar-
isons (Fig. 2).
Association between HindIII and PvuII polymorphisms.
A contingency table relating HindIII and PvuII polymor-
phisms is presented in Table 4. Observed and expected
numbers of cases are shown. The null hypothesis, that the
genotypes were independent, was rejected by chi-square
testing (chi-square 5 95, p , 0.0001), demonstrating
strong linkage disequilibrium between the HindIII and
PvuII polymorphisms, an observation also noted by others
(12,20,22).
Estimated haplotypic frequencies by disease. Table 5
presents the estimated frequencies of haplotypes that best
account for the observed genotypic associations, both overall
and by CAD status. In CAD patients, the estimated
frequency for the HindIII (1)/PvuII (2) (H1P2) haplo-
type is nominally greater than for control subjects, whereas
for the other haplotypes, estimated frequencies are less than
(H1P1, H2P1) or similar to (H2P2) control subjects.
Adjusted odds ratio estimates using conditional logistic
regression. For angiographic CAD, multivariate logistic
regression (simultaneously considering age, gender, choles-
terol, hypertension, diabetes, smoking status, presence of
HindIII [1] allele or presence of PvuII [2] allele) selected
male gender (OR 5 4.5), age (OR 5 1.05 per year older),
HindIII (1) allelic carriage (OR 5 2.86, CI 1.50 to 5.42,
p 5 0.0014), diabetes (OR 5 1.92) and (trend) PvuII (2)
allelic carriage (OR 5 1.42, CI 0.95 to 2.12, p 5 0.09) as
independent associates (Table 6). Hence, the positive asso-
ciations with CAD and HindIII (1) allelic carriage and
PvuII (2) allelic carriage were maintained or amplified after
adjustment for known, measured risk factors (compare with
Table 3).
DISCUSSION
Summary of study results. In a relatively large, prospec-
tively studied, angiographically defined population, we
found associations with CAD for common LPL polymor-
phisms that were of moderate strength for carriage of the
HindIII (1) allele (heterozygotic or homozygotic genotype)
and of modest strength (trend only) for the PvuII (2) allele.
Adjusted simultaneously for six CAD risk factors, the
associations persisted and were strengthened (HindIII [1]
adjusted OR 5 2.9; PvuII [2] adjusted OR 5 1.4).
Linkage disequilibrium of polymorphisms. A strong link-
age disequilibrium, also reported by others, was found between
the HindIII and PvuII variant polymorphisms (12,13,15–
17,20,22). Linkage disequilibrium, the tendency of a specific
combination of alleles at two (or more) linked loci to occur on
the same chromosomal homologue more frequently than
explained by chance, is determined by the proximity of the
genetic loci, the rate of spontaneous mutation and the gener-
ational time since a mutation of interest occurred on the
ancestral chromosome. Paradoxically, the direction of the
association with CAD differed for the two polymor-
Table 2. Genotypic Distributions and Allelic Frequencies of HindIII and PvuII Polymorphisms
Among CAD Patients and Control Subjects
Group
Genotype
(2/2),
% (n)
Genotype
(2/1),
% (n)
Genotype
(1/1),
% (n)
Allele (2),
% (fraction)
HindIII polymorphism
CAD (n 5 483) 6.2 (30) 40.2 (194) 53.6 (259) 26.3 (254/966)
No CAD (n 5 168) 13.1 (22) 31.0 (52) 56.0 (94) 28.6 (96/336)
PvuII polymorphism
CAD (n 5 483) 21.7 (105) 48.9 (236) 29.4 (142) 46.2 (446/966)
No CAD (n 5 168) 19.0 (32) 45.2 (76) 35.7 (60) 41.7 (140/336)
For 2 3 3 table of genotype by disease, p 5 0.006 for HindIII, p 5 0.31 for PvuII.
CAD 5 coronary artery disease.
Table 3. Odds Ratios for CAD Associated With Carriage of
HindIII- and PvuII-Carrying Genotypes
Odds Ratio (CI) p
HindIII genotypes
HindIII (1/1) vs. HindIII (2/2) 2.02 (1.11 to 3.70) 0.020
HindIII (1/2) or HindIII (1/1)
vs. HindIII (2/2)
2.28 (1.27 to 4.00) 0.005
PvuII genotypes
PvuII (2/2) vs. PvuII (1/1) 1.39 (0.84 to 2.28) 0.20
PvuII (2/2) or PvuII (2/1) vs.
PvuII (1/1)
1.33 (0.92 to 1.93) 0.13
CAD 5 coronary artery disease; CI 5 confidence interval.
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phisms, with the more common (1) allele being associated
with increased risk for HindIII but decreased risk (trend) for
the more common PvuII (1) allele. One explanation for this
paradox, consistent with our data (Table 6), is a third, linked,
disease-causing mutation, located on HindIII (1)/PvuII (2)
haplotypic chromosomes, which originated on a HindIII (1)
chromosome before the mutation causing the PvuII site
variation, as discussed below (22).
Comparison with literature reports. Associations of poly-
morphisms with altered plasma lipids and lipoproteins. A
number of previous studies have defined associations of the
HindIII and PvuII polymorphisms with plasma lipids and
lipoproteins. The HindIII (1) allele or HindIII (1/1)
genotype has been found to be associated with elevated
triglycerides and/or decreased HDL cholesterol in several
(13,16,17,19,20,22,23) although not all (15,21) studies.
Gerdes et al. found a negative gene-dosage effect of the
HindIII (1) allele on HDL (but not total) cholesterol (22),
and the large ECTIM study also reported lower HDL
cholesterol in association with HindIII (1) (20).
In contrast, the PvuII polymorphism has not been associ-
ated with consistent changes in specific lipids or lipoprotein
concentrations, and hence its associated risk often has been
attributed to other or more subtle effects (13,15–17,19–22).
Associations of polymorphisms with altered risk of atherosclero-
sis. Earlier, mostly small studies have not adequately de-
fined associations between LPL polymorphisms and CAD.
Several (14,19,20,22) but not all (12,16,21) studies have
suggested that HindIII (1) allele or HindIII (1/1) geno-
type to be associated with measures of ischemic heart
disease, whereas associations with PvuII polymorphisms
have been inconsistent or absent (12,16,19–21). Thorn et
al. found increased HindIII (1) allelic or HindIII (1/1)
genotypic frequencies in patients with coronary atheroscle-
rosis (14), whereas Peacock et al. observed no differences in
either HindIII or PvuII allelic frequencies in young MI
survivors (16). Ukkola et al. found reductions in various
measures of ischemic heart disease in non–insulin-
dependent diabetics who were PvuII (1/1) but increases in
those who were HindIII (2/2) (21). In contrast, Gerdes et
al. found the HindIII (1/1) genotype to be positively
associated with a family history of premature ischemic heart
disease in 40-year old Danish men (22). Similarly, Mattu et
al. found an association between the HindIII (1) allele (but
not the PvuII [1] allele) and CAD (19). Also, the ECTIM
case–control study (20) reported an increased odds ratio
(2.1) for MI with HindIII (1/1) compared with HindIII
(2/2) genotypes. Wang et al. (12) found an association
between extent but not occurrence of CAD and PvuII
(PvuII [1/1]) but not HindIII polymorphisms.
Our study adds substantially to previous evidence for an
association between the HindIII (1) allele and CAD in
terms of both size and the certainty of diagnosis (angio-
graphic). Our minor (if any) association between PvuII (2)
carriage and CAD differs from two reports (12,20) but is
consistent with three others (16,19,21). These differences
are likely explained by differences in trial size and design,
ethnic/genetic makeup, disease marker, and chance (given
the relatively modest degrees of association, especially for
PvuII). In addition, though these two genetic polymor-
phisms are linked to each other, it is possible that they
function primarily as markers for another linked, etiologi-
cally important genomic locus (see next section).
Pathophysiologic rationale for study findings. The catab-
olism of chylomicrons and VLDL by LPL results in the
formation of chylomicron remnants depleted in triglyceride
but enriched in cholesteryl esters (a result of cholesteryl ester
transfer protein) and intermediate density lipoproteins;
intermediate density lipoproteins are further metabolized to
LDL (8,22,23). A further function of LPL is to bind and
Table 4. Associations Between HindIII and PvuII Polymorphisms: Observed (Expected)
Genotypic Frequencies
HindIII (2/2) HindIII (2/1) HindIII (1/1) Totals
PvuII (2/2) 33 (10.8) 64 (53.3) 46 (78.9) 143
PvuII (2/1) 16 (27.5) 151 (135.2) 196 (200.3) 363
PvuII (1/1) 6 (16.6) 55 (81.6) 158 (120.8) 219
Totals 55 270 400 725
Data are presented as observed numbers of cases and expected numbers of cases (in parentheses) for each cell. By chi-square
testing, the null hypothesis of independence of genotypes is rejected, chi-square 5 94.8, p , 0.0001.
Table 5. Estimated Haplotypic Frequencies With Association
Group H1P1 H1P2 H2P1 H2P2 D LTS p Value
Overall 0.476 0.262 0.077 0.186 0.068 78.4 ,0.001
CAD1 0.465 0.272 0.074 0.189 0.068 48.4 ,0.001
CAD2 0.490 0.224 0.093 0.192 0.073 25.9 ,0.001
Estimated frequencies calculated using the linkage utility program EH assuming association.
CAD 5 coronary artery disease; H 5 HindIII; LTS 5 Likelihood Test Statistic; P 5 PvuII.
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travel with chylomicron remnants to the liver, where LPL
enhances clearance of chylomicron remnants via LDL
receptor-related protein (33). In the liver, triglyceride-
enriched particles (including HDL and LDL) also are
catabolized by another, related hydrolytic enzyme, hepatic
lipase (22).
Given its complex and central role, dysfunctional LPL
could affect lipoprotein metabolism in a number of ways,
although the precise mechanism of enhanced atherogenesis
is unclear. A change in LPL’s lipolytic or clearance func-
tions for triglyceride-rich lipoproteins and their remnants
has been postulated, resulting in a more atherogenic lipid
phenotype in fasting or postprandial states (22,33–35).
Because both HindIII and PvuII polymorphisms involve
introns (ie., 8, 6) in the LPL gene on chromosome 8 (15),
protein structure should not be affected; however, their
operation as risk markers could be explained through
linkage disequilibrium with one (or more) etiologic genetic
locus in close proximity.
Gerdes et al. postulated LPL variants to be associated with
altered triglyceride metabolism, with HDL cholesterol alter-
ations serving as an integrative marker of triglyceride metabo-
lism (22). They interpreted their findings to suggest that the
responsible variant was located on HindIII (1)/PvuII (2)
haplotypic chromosomes and had originated on a HindIII (1)
chromosome before the mutation causing the PvuII site
variation (22). Similarly, we interpret our data to be consistent
with a genetic variant of LPL or a closely linked, disease-
causing gene that is associated with HindIII (1)/PvuII (2)
haplotypes (cf. Table 6) and believe that this hypothesis, along
with other possible explanations, warrants investigation.
Study strengths and limitations. This study has the ad-
vantage of being of relatively large size and angiographically
controlled. The possibility exists of inadvertent genetic
selection bias appearing in patients selected for coronary
angiography, compared with a free-living population sam-
ple. However, if present, it appears to be small, given the
similarity in the LPL polymorphic allelic frequencies in our
angiographic study and in several other studies from healthy
populations (12–23). Also, we adjusted our odds ratios for
well known CAD risk factors, including age and gender,
and found that the associations persisted and, indeed, were
strengthened. At least, the study is clinically relevant for the
group of subjects who present for angiographic evaluation
because of a suspicion of CAD.
Mistyping is a theoretical concern and was dealt with by
retyping '10% of our samples, with identical results. Also,
polymorphic allelic frequencies are similar to those reported
in other white populations (12–23).
Our study was cross-sectional, raising the possibility of
changes in prevalence of LPL polymorphisms among cases
and control subjects due to differential survival rates for
CAD patients presenting for angiography based on LPL
genotype status. This seems unlikely, but can be addressed
by prospective studies. Disease and control groups differed
in some baseline variables, as expected. However, when
differences were accounted for by conditional multivariate
logistic regression, the relative risk associated with the
polymorphisms was maintained or augmented.
Conclusions. In a moderately large, prospectively studied,
angiographically defined U.S. population of European ex-
traction, the common LPL polymorphisms HindIII (adjust-
ed OR 5 2.9) and, possibly, PvuII (adjusted OR 5 1.4)
were associated with angiographic CAD. Given the central
importance of LPL to lipid metabolism and the prevalence
of these polymorphisms, additional investigation is war-
ranted. Whether genotyping will be useful in individual risk
assessment will require further study.
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